@article{10902/30013,
year = {2023},
url = {https://hdl.handle.net/10902/30013},
abstract = {Background: MOTS-c and Romo1 are mitochondrial peptides that are modulated by
oxidative stress. No previous studies have explored circulating levels of MOTS-c in
patients with chronic obstructive pulmonary disease (COPD).
Methods: We enrolled 142 patients with stable COPD and 47 smokers with normal
lung function in an observational cross-sectional study. We assessed serum levels of
both MOTS-c and Romo1 and associated these findings with clinical characteristics
of COPD.
Results: Compared with smokers with normal lung function, patients with COPD
had lower levels of MOTS-c (p = 0.02) and higher levels of Romo1 (p = 0.01). A
multivariate logistic regression analysis revealed that above-median MOTS-c levels
were positively associated with Romo1 levels (OR 1.075, 95% CI 1.005–1.150, p =
0.036), but no association was found with other COPD characteristics. Below-median
levels of circulating MOTS-c were associated with oxygen desaturation (OR 3.25 95%
CI 1.456–8.522, p = 0.005) and walking <350 meters (OR 3.246 95% CI 1.229–8.577,
p = 0.018) in six-minute walk test. Above-median levels of Romo1 were positively
associated with current smoking (OR 2.756, 95% CI 1.133–6.704, p = 0.025) and
negatively associated with baseline oxygen saturation (OR 0.776 95% CI 0.641–0.939,
p = 0.009).
Conclusions: Reduced levels of circulating MOTS-c and increased levels of Romo1
were detected in patients diagnosed with COPD. Low levels of MOTS-c were
associated with oxygen desaturation and poorer exercise capacity using 6 min walk
test. Romo1 was associated with current smoking and baseline oxygen saturation},
organization = {Funding: This study was funded by Instituto de Investigación Sanitaria of Cantabria (IDIVAL): NextVAL grant: NVAL19/01. This study received funding from GSK (NCT04449419). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decisión to submit it for publication. GSK was provided the opportunity to review a preliminary version of this manuscript for factual accuracy, but the authors are solely responsible for final content and interpretation.
Acknowledgments: We want to particularly acknowledge the patients and the Biobank Valdecilla (PT17/0015/0019) integrated in the Spanish Biobank Network for its collaboration.},
publisher = {Frontiers Media S.A.},
publisher = {Frontiers in Medicine, 2023, 10, 1100211},
title = {Circulating levels of mitochondrial oxidative stress-related peptides MOTS-c and Romo1 in stable COPD: a cross-sectional study},
author = {Amado Diago, Carlos Antonio and Martín-Audera, Paula and Agüero Calvo, Juan and Lavín Gómez, Bernardo Alio and Guerra Ruiz, Armando Raúl and Boucle, Daymara and Ferrer Pargada, Diego José and Berja, Ana and Martín, Fernando and Casanova, Ciro and García Unzueta, María Teresa},
}